The anti-vascular endothelial growth factor drugs ranibizumab and aflibercept, used to treat vision loss from diabetic macular edema (DME), and approximately 20 to 30 times more expensive than bevacizumab, are not cost - effective for treatment of DME compared to bevacizumab unless their prices decrease substantially, according to a study published online by JAMA Ophthalmology. (sciencedaily.com)
The new eye studies showcase a drug called ranibizumab, which is a fragment of the cancer drug. (sciencenews.org)
BACKGROUND AND OBJECTIVE To determine outcomes of intravitreal ranibizumab (IVR)(Lucentis; Genentech, South San Francisco, CA) versus bevacizumab (IVB)(Avastin; Genentech, South San Francisco, CA) (semanticscholar.org)